ZEOX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ZEOX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Zeo ScientifiX's revenue for the three months ended in Jan. 2024 was $1,154 Mil. Its revenue for the trailing twelve months (TTM) ended in Jan. 2024 was $1,157 Mil. Zeo ScientifiX's Revenue per Share for the three months ended in Jan. 2024 was $0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Jan. 2024 was $0.48.
Warning Sign:
Zeo ScientifiX Inc revenue per share is in decline over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of Zeo ScientifiX was -41.90% per year. During the past 3 years, the average Revenue per Share Growth Rate was 422.90% per year. During the past 5 years, the average Revenue per Share Growth Rate was 246.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 13 years, Zeo ScientifiX's highest 3-Year average Revenue per Share Growth Rate was 582.60% per year. The lowest was -4.60% per year. And the median was 36.30% per year.
The historical data trend for Zeo ScientifiX's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zeo ScientifiX Annual Data | |||||||||||||||||||||
Trend | Oct14 | Oct15 | Oct16 | Oct17 | Oct18 | Oct19 | Oct20 | Oct21 | Oct22 | Oct23 | |||||||||||
Revenue | Get a 7-Day Free Trial | 1.70 | 3.06 | 5.60 | 6.49 | 4.56 |
Zeo ScientifiX Quarterly Data | ||||||||||||||||||||
Apr19 | Jul19 | Oct19 | Jan20 | Apr20 | Jul20 | Oct20 | Jan21 | Apr21 | Jul21 | Oct21 | Jan22 | Apr22 | Jul22 | Oct22 | Jan23 | Apr23 | Jul23 | Oct23 | Jan24 | |
Revenue | Get a 7-Day Free Trial | 1,070.00 | 0.85 | 1.22 | 1.42 | 1,154.00 |
For the Biotechnology subindustry, Zeo ScientifiX's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Zeo ScientifiX's Revenue distribution charts can be found below:
* The bar in red indicates where Zeo ScientifiX's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,157 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zeo ScientifiX (OTCPK:ZEOX) Revenue Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Thank you for viewing the detailed overview of Zeo ScientifiX's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Skycrest Holdings, Llc | 10 percent owner | 1930 HARRISON STREET, SUITE 204, HOLLYWOOD FL 33020 |
Harry L. Leider | director, officer: CEO and Director | C/O GELESIS, INC., 501 BOYLSTON STREET, SUITE 6102, BOSTON MA 02116 |
Howard Lawrence Golub | officer: Executive Vice President & CSO | 23648 SEPTEMBER SUN SQ, ASHBURN VA 20148 |
Matthew Phillip Sinnreich | officer: COO and Acting CEO | 4045 SHERIDAN AVENUE, SUITE 239, MIAMI BEACH FL 33139 |
Steven Jerry Glauser | director | 1428 BRICKELL AVENUE, SUITE 105, MIAMI FL 33131 |
Leathem S Stearn | director | 2306 BAY DRIVE, POMPANO BEACH FL 33062 |
Charles Luther Bretz | director | 58 N. CHICAGO ST, 2ND FLOOR, JOLIET IL 60432 |
Bhupendra Kumar Modi | director | 6 MARINA BOULEVARD, #63-18, THE SALE @ MARINA BAY U0 018985 |
Gurvinder Pal Singh | director | E - 128, FIRST FLOOR, GREATER KAILASH - II, NEW DELHI K7 110048 |
John F Chiste | director | |
Ryan C Likes | officer: Chief Operating Officer | 1116 MEADOWBROOK AVE., LOS ANGELES CA 90019 |
Greyt Ventures, Llc | 10 percent owner | GREYT VENTURES, LLC, 20533 BISCAYNE BOULEVARD, SUITE 648, AVENTURA FL 33180 |
Wendy Grey | 10 percent owner | GREYT VENTURES, LLC, 20533 BISCAYNE BOULEVARD, SUITE 648, AVENTURA FL 33180 |
Ian T Bothwell | 10 percent owner, officer: Chief Financial Officer | 77 530 ENFIELD LANE, BLDG D, PALM DESERT CA 92211 |
Albert Mitrani | director, officer: Chief Executive Officer | 4045 SHERIDAN AVE., SUITE 239, MIAMI BEACH FL 33140 |
From GuruFocus
By Marketwired Marketwired • 08-06-2020
By PRNewswire PRNewswire • 11-09-2021
By Marketwired Marketwired • 10-20-2020
By PRNewswire PRNewswire • 01-30-2019
By Marketwired Marketwired • 05-05-2020
By ACCESSWIRE ACCESSWIRE • 07-26-2022
By ACCESSWIRE ACCESSWIRE • 08-30-2022
By ACCESSWIRE ACCESSWIRE • 06-21-2023
By Marketwired Marketwired • 05-27-2020
By Marketwired Marketwired • 05-19-2020
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.